Marksans Pharma Limited

MARKSANS

INE750C01026

Pharmaceuticals

Delayed NSE India S.E. Other stock markets 06:29:40 2024-09-18 am EDT			5-day change	1st Jan Change
281.22 ^INR	-5.12%		+8.84%	+74.56%

Aug. 21	Marksans Pharma Arm Gets UK Regulator's Marketing Nod for Fluoxetine Capsules	MT
Aug. 20	Marksans Pharma Gets US FDA's EIR for Goa, India Unit	MT

Marksans Pharma Limited Appoints Shailaja Vardhan as an Independent Director

August 28, 2023 at 08:13 am EDT

M Marksans Pharma Limited announced that at its AGM held on 28th August, 2023, the shareholders approved the appointment of Mrs. Shailaja Vardhan as an Independent Director of the Company.

Latest news about Marksans Pharma Limited

Marksans Pharma Arm Gets UK Regulator's Marketing Nod for Fluoxetine Capsules	Aug. 21	MT
Marksans Pharma Gets US FDA's EIR for Goa, India Unit	Aug. 20	MT
Successful Closure of US FDA Inspection At Marksans Pharma's Manufacturing Facility Located At Verna, Goa	Aug. 20	CI
Marksans Pharma Seeks M&A	Aug. 14	CI
Transcript : Marksans Pharma Limited, Q1 2025 Earnings Call, Aug 14, 2024	Aug. 14
Marksans Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2024	Aug. 13	CI
Marksans Pharma Arm Gets UK Regulator's Nod for Levonorgestrel Tablet	Aug. 02	MT
Marksans Pharma Gets UK Regulator's Nod for Two Products	Jul. 02	MT
Transcript : Marksans Pharma Limited, Q4 2024 Earnings Call, May 31, 2024	May. 31
INDIA STOCKS-Indian shares fall for fifth session on weak global cues, election uncertainties	May. 30	RE
Marksans Pharma's Consolidated Profit Declines in Fiscal Q4; Shares Fall 9%	May. 30	MT
Marksans Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	May. 30	CI
Marksans Pharma Limited Recommends Final Dividend for the Financial Year 2023-24	May. 30	CI
Marksans Pharma Gets Marketing Approval for Levetiracetam Relonchem in UK	May. 28	MT
Marksans Pharma's Goa Facility Gets Five Inspectional Observations from US FDA	Apr. 18	MT
Transcript : Marksans Pharma Limited Presents at Bharat Connect Conference - Rising Stars 2024, Mar-26-2024	Mar. 25
Transcript : Marksans Pharma Limited, Q3 2024 Earnings Call, Feb 14, 2024	Feb. 14
Marksans Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 13	CI
Transcript : Marksans Pharma Limited, Q2 2024 Earnings Call, Nov 09, 2023	Nov. 09
Marksans Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 09	CI
Marksans Pharma Arm Gets UK Regulator's Approval to Market Cyanocobalamin Tablets	Nov. 06	MT
Marksans Pharma Undergoes Successful Inspection from German Health Authorities	Nov. 01	MT
CARE Affirms A+ Rating on Marksans Pharma's Long-term Bank Financing; Outlook Stable	23-10-12	MT
Marksans Pharma Gets US FDA Nod for Esomeprazole Magnesium Delayed-Release Capsules	23-10-03	MT
Marksans Pharma Limited Announces US FDA Approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg	23-10-03	CI

Marksans Pharma Limited is an India-based company, which is engaged in research, manufacturing and marketing of generic pharmaceutical formulations in the global markets. The Company's product portfolio spreads various therapeutic segments of cardiovascular system (CVS), central nervous system (CNS), antidiabetic, pain management, cough and cold, gastroenterological, and anti-allergies. Its product portfolio includes tablets (plain, enteric-coated and film-coated), hard capsules, soft gelatin capsules, oral liquids and ointments. Its consumer self-care products (over the counter) include pain management, upper respiratory, digestive health, vitamins minerals and supplements (VMS) and skin care products. The Company's prescription - Rx therapeutic segments include CVS, CNS, oncology, anti-diabetics and anti-biotic. Its end consumers include retail chains, pharmacy stores, hospitals and institutions. It has manufacturing facilities in India, the United Kingdom and the United States.

Employees

1,141

Sector

Pharmaceuticals

Calendar

2024-09-24 - Annual General Meeting

More about the company